What is Diligent Pharma?
Diligent Pharma operates as a private vendor management qualification organization. The company provides a centralized technology platform designed to streamline the complex process of vendor qualification within clinical trial execution. This focus addresses a critical need for efficiency and compliance in the pharmaceutical research sector.
How much funding has Diligent Pharma raised?
Diligent Pharma has raised a total of $8.3M across 1 funding round:
Series A
$8.3M
Series A (2023): $8.3M with participation from Point Judith Capital, GenHenn Capital, and FCA Venture Partners
Key Investors in Diligent Pharma
Point Judith Capital
Point Judith Capital is an early-stage venture capital firm based in Boston, Massachusetts, founded in 2001, focused on supporting entrepreneurs.
GenHenn Capital
GenHenn Capital is an undisclosed investor participating in the funding round.
FCA Venture Partners
FCA Venture Partners is an investment firm with over 15 years of experience in healthcare, focusing on companies that enhance patient care, empower providers, and reduce costs, operating from Nashville and Charlotte.
What's next for Diligent Pharma?
The recent major strategic investment positions Diligent Pharma for accelerated growth and enhanced market penetration. This capital is expected to fuel further development of its vendor management platform, expand its service offerings, and strengthen its competitive advantage in the clinical trial support ecosystem. The company is poised to leverage this backing to solidify its enterprise-level standing and drive innovation in vendor qualification technologies.
See full Diligent Pharma company page
